27 July 2023 in Nature Reviews Methods Primers
18 May 2023 in Journal of Extracellular Vesicles
The analysis of extracellular vesicles (EV) in blood samples is under intense investigation and holds the potential to deliver clinically meaningful biomarkers for health and disease. Technical variation must be minimized to confidently assess EV‐associated biomarkers, but the impact of pre‐analytics on EV characteristics in blood samples remains minimally explored. We present the results from the first large‐scale EV Blood Benchmarking (EVBB) study in which we systematically compared 11 blood collection tubes (BCT; six preservation and five non‐preservation) and three blood processing intervals (BPI; 1, 8 and 72 h) on defined performance metrics (n = 9). The EVBB study identifies a significant impact of multiple BCT and BPI on a diverse set of metrics reflecting blood sample quality, ex‐vivo generation of blood‐cell derived EV, EV recovery and EV‐associated molecular signatures. The results assist the informed selection of the optimal BCT and BPI for EV analysis. The proposed metrics serve as a framework to guide future research on pre‐analytics and further support methodological standardization of EV studies.
9 November 2023 in Journal of Extracellular Vesicles
Extracellular vesicles (EVs) in blood plasma are recognized as potential biomarkers for disease. Although blood plasma is easily obtainable, analysis of EVs at the single particle level is still challenging due to the biological complexity of this body fluid. Besides EVs, plasma contains different types of lipoproteins particles (LPPs), that outnumber EVs by orders of magnitude and which partially overlap in biophysical properties such as size, density and molecular makeup. Consequently, during EV isolation LPPs are often co‐isolated. Furthermore, physical EV‐LPP complexes have been observed in purified EV preparations. Since co‐isolation or association of LPPs can impact EV‐based analysis and biomarker profiling, we investigated the presence and formation of EV‐LPP complexes in biological samples by using label‐free atomic force microscopy, cryo‐electron tomography and synchronous Rayleigh and Raman scattering analysis of optically trapped particles and fluorescence‐based high sensitivity single particle flow cytometry. Furthermore, we evaluated the impact on flow cytometric analysis in the presence of LPPs using in vitro spike‐in experiments of purified tumour cell line‐derived EVs in different classes of purified human LPPs. Based on orthogonal single‐particle analysis techniques we demonstrate that EV‐LPP complexes can form under physiological conditions. Furthermore, we show that in fluorescence‐based flow cytometric EV analysis staining of LPPs, as well as EV‐LPP associations, can influence quantitative and qualitative EV analysis. Lastly, we demonstrate that the colloidal matrix of the biofluid in which EVs reside impacts their buoyant density, size and/or refractive index (RI), which may have consequences for down‐stream EV analysis and EV biomarker profiling.
28 March 2024 in Journal of Extracellular Vesicles
Extracellular vesicles (EVs) contain a plethora of biomolecules, including nucleic acids, with diverse diagnostic and therapeutic application potential. Although reverse transcription‐quantitative PCR (RT‐qPCR) is the most widely applied laboratory technique to evaluate gene expression, its applicability in EV research is challenged by the lack of universal and stably present reference genes (RGs). In this study, we identify, validate and establish SNRPG, OST4, TOMM7 and NOP10 as RGs for the normalization of EV‐associated genes by RT‐qPCR. We show the stable presence of SNRPG, OST4, TOMM7 and NOP10 in multiple cell lines and their secreted EVs (n = 12) under different (patho)physiological conditions as well as in human‐derived biofluids (n = 3). Enzymatic treatments confirm the presence of SNRPG, OST4, TOMM7 and NOP10 inside EVs. In addition, the four EV‐associated RGs are stably detected in a size‐range of EV subpopulations. RefFinder analysis reveals that SNRPG, OST4, TOMM7 and NOP10 are more stable compared to RGs established specifically for cultured cells or tissues such as HMBS, YWHAZ, SDHA and GAPDH. In summary, we present four universal and stably present EV‐associated RGs to enable normalization and thus steer the implementation of RT‐qPCR for the analysis of EV‐associated RNA cargo for research or clinical applications.
7 August 2023 in Journal of Extracellular Vesicles
Despite an enormous interest in understanding the bioactivity of extracellular vesicles (EV) in physiology and disease for the development of therapeutic applications, the impact of EV preparation methods remains minimally explored. In this study, we implemented density gradient ultracentrifugation combined with size‐exclusion chromatography (DG‐SEC), differential ultracentrifugation (dUC) and/or stand‐alone SEC (sSEC) to fractionate media conditioned by different cancer cells and/or cancer‐associated fibroblasts (CAF). EV‐enriched but protein‐depleted versus EV‐depleted but protein‐enriched DG‐SEC fractions, and EV‐containing dUC and sSEC preparations were quality controlled for particle number, protein concentration, selected protein composition and ultrastructure, characterized for their cytokine content, and dose‐dependently evaluated for monocyte‐derived dendritic cell (MoDC) maturation by measuring surface marker expression and/or cytokine secretion. EV preparations obtained by DG‐SEC from media conditioned by different cancer cell lines or CAF, were depleted from soluble immune suppressive cytokines such as VEGF‐A and MCP‐1 and potently stimulated MoDC maturation. In contrast, EV‐containing dUC or sSEC preparations were not depleted from these soluble cytokines and were unable to mature MoDC. Subsequent processing of dUC EV preparations by SEC dose‐dependently restored the immunomodulatory bioactivity. Overall, our results demonstrate that method‐dependent off‐target enrichment of soluble cytokines has implications for the study of EV immunomodulatory bioactivity and warrants careful consideration.
8 April 2025 in Nature Protocols